A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

NCT05048719 on ClinicalTrials.gov · last registry update 2023-10-17

An unusually large phase 2: 383 participants, more than double the 110 typical for the stage. The sponsor logged completion for 30 September 2022. Primary outcome, as filed: Change From Baseline in HbA1c in LY3502970 as Compared to Placebo. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 383
Started: 2021-09-15
Primary completion: 2022-09-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in HbA1c in LY3502970 as Compared to Placebo

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.